Objectif
"The healthcare industry is experiencing unprecedented rates of drug failure, long development times and high costs - because current lab tests and disease models (in vitro) don’t adequately predict drug effect in the patient (in vivo).
To address this “Challenge”, three leading EU SMEs; Luxcel Biosciences Ltd, Axiogenesis AG and BMG Labtech GmbH, are partnering to bring to market, a fully integrated targeted metabolomics Test Platform, comprising physiologically relevant in vitro cell assays and easy to use test kits, configured for use with the multimode fluorescence plate reader; instrumentation, which is installed in, or else is easily accessible to every cell biology lab globally.
The innovation “Solution"" is made possible by Luxcel’s unique and patented optical nanosensor technology, and its integration to create entirely new ‘functionally-connected’ in vitro tests. The scope of the project is to finalize development of the cell-based assay platform towards market introduction, productise, pilot and demonstrate it with key opinion leaders; for modular product launch through the project and full launch early 2019.
Leveraging existing global sales channels, the three industrial partners are targeting revenues of EUR 15 million by 2023. In total, about 24-29 new jobs will be created by 2023; with 6 new jobs during the project. All three SMEs are passionate about the MetaCell-TM solution, and expect that a successful outcome will see them positioned as No. 1 in their respective fields in Europe and internationally.
"
Champ scientifique
Programme(s)
Régime de financement
IA - Innovation actionCoordinateur
T12 Cork
Irlande
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.